Gene Holdings ( ($ENGN) ) has issued an announcement. enGene Holdings Inc. has reported promising preliminary data from its Phase 2 LEGEND trial ...

Social media health influencers are busy doing what they do best which is churning out click bait to help line their pockets.

The trend involves anonymous urinators, football fields and a bizarre TikTok saga that has us all questioning our life ...

Greater adherence to the Mediterranean diet is associated with reduced prevalence of overactive bladder (OAB), according to a ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Becoming a blockbuster in its third full year on the market put Gilead’s cancer treatment Trodelvy on a course to potentially justify the company’s $21 billion ...

An international investigation uncovers how criminal networks traffick parts of the totoaba, an endangered fish caught in ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3.

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The Buffaloes, at 3-7 overall and 1-6 in Big 12 play, have been among the worst Power 4 teams in the country this fall.